NEW YORK--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive data ...
ATLANTA — The investigational ultra long-acting injectable GLP-1 receptor agonist (RA) MET-097 produced up to 14% weight loss, with the potential for improved tolerability compared with other GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback